SFDA cracks down on unregistered peptide sales via online platforms

The Saudi Food and Drug Authority (SFDA) has detected several unregistered peptide products being promoted and sold through websites and social media accounts without obtaining the necessary licenses from the authority. This action is part of SFDA’s ongoing efforts to monitor products sold through electronic channels and to verify their legal registration and safe circulation.

The authority explained that these products are unregistered, of unknown origin, and do not meet approved requirements for safe transport, storage, or pharmaceutical supply chain standards. As a result, their safety, quality, and handling conditions cannot be verified. SFDA noted that some websites and accounts used misleading marketing claims suggesting the products are tested, high-quality, or reliable, potentially giving consumers a false impression of their safety or approval. The authority stated that these sites and accounts were identified after confirming they did not meet registration and legal distribution requirements, and that they marketed products through unlicensed platforms. SFDA affirmed that legal action will be taken against violators.

The authority clarified that these violations fall under Article 34, Paragraph 2, of the Law on Pharmaceutical and Herbal Establishments and Products, which prohibits the sale, dispensing, or possession of unregistered pharmaceutical products for commercial purposes. Penalties can reach up to five million riyals (SAR) in fines, imprisonment for up to five years, or both.

SFDA stressed that circulating unregistered or unknown-source products may endanger consumer health and safety, as their compliance with approved standards cannot be verified. Using such products without medical supervision could pose health risks. The authority has taken legal measures against the owners of the violating online stores, preparing to refer them to the Public Prosecution. SFDA added that it continues to monitor and inspect online sites and platforms to ensure compliance with regulations, enhance product safety, and protect public health.

The authority urged the public to verify the source and legal registration of products before purchasing, and to avoid obtaining pharmaceutical products from untrusted or unlicensed sources.